华森制药(002907.SZ)：HSN002066C1片药物临床试验获批准

Core Viewpoint - Huason Pharmaceutical's subsidiary, Chongqing Huason Inno Biotech Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HSN002066C1 tablets, a selective PARP7 inhibitor for treating advanced malignant solid tumors [1] Group 1 - HSN002066C1 tablets, with the free base HSN002B015, are independently developed by Huason Inno and fully owned in terms of intellectual property rights [1] - The drug is intended for oral administration and has shown significant tumor suppression activity in various tumor models when used alone or in combination [1] - HSN002066C1 is characterized as a potent and highly selective PARP7 inhibitor, demonstrating high exposure levels in mice [1]